3R Research Foundation Switzerland - Front page
The foundation


de | fr | en   print view

Annual report 2002

1. Structure of the Foundation

The Foundation is a cooperative institution set up by the Parliamentary Group for Animal Experimentation Questions (public organ), Interpharma (Novartis Pharma Ltd, F. Hoffmann-La Roche Ltd, Serono Ltd) and the Foundation for Animal-Free Research (animal protection). It was entered in the commercial register on 18th August, 1987.

The funds provided to subsidise research stem from the Federal Veterinary Office and Interpharma.

2. Purpose of the Foundation

The purpose of the 3R Research Foundation Switzerland is to promote alternative research methods which avoid the use of animals through grants for research projects. The organisation supports first and foremost projects aimed at developing new methods or refining accepted methods (validation) which offer practical improvements vis-à-vis standard animal experimentation in line with the 3R motto Reduce, Refine, Replace.

A broad range of projects is sponsored on the condition that they are likely to reduce the number of animals used or the stress and/or pain suffered. Projects considered must be based on the Foundation's three principles and are mainly in the bio-medical multidisciplinary field.

3. Activities during 2002

In its sixteenth year of existence the Administrative Board met twice, in April and December, for a half-day meeting. Apart from the statutory business concerning the end of the business year 2001, the Board addressed the following issues.

Research funds for 2002 were allotted to 10 projects already underway. In addition, 4 new projects were approved, while 9 applications were rejected. The Board also took note of the final assessment by the Evaluation Committee of 4 projects which had been completed. In April administrative questions in connection with the submission of projects were clarified through a change in the guidelines. In December the Administrative Board received a new promise of funds from Interpharma amounting to Sfr. 2.4 million. Together with the corresponding contributions from the Federal Veterinary Office, this means that the continuation of the Foundation's activities is ensured.

The scientific adviser represented the Foundation at the 4th World Congress on Alternatives and Animal Use in the Life Sciences held in August 2002 in New Orleans. In November 2002 the 3R Research Foundation became a member of the European consensus platform for 3R alternatives (ECOPA) based in Brussels, which has been re-founded on the basis of new statutes. This means that it is now part of a European network along with Austria, Belgium, the Czech Republic, Denmark, Germany, Finland, Italy, the Netherlands, Norway, Poland, Spain, Sweden and the UK (14 countries in all). The aim of this association is to promote the international exchange of information about projects relevant to the 3R principle and to facilitate paneuropean efforts and coordination.

With the support of the scientific advisor, the Evaluation Committee held two meetings during the year, where in particular they assessed new applications and evaluated completed projects. The scientific adviser's tasks included publishing the 3R Info Bulletin (as a brochure and on the Foundation's Internet site at www.forschung3r.ch), writing brief scientific reports in English which present the projects receiving funding and keeping the Foundation's Internet site up-to-date. He was also busy working with Oekosophie GmbH to create a training model for 3R requirements via the Internet (module for further training of specialists who carry out animal experiments). Much time was also devoted to advising applicants and project leaders, calling for intermediate reports, evaluating draft projects and dealing with enquiries and explanations for the rejection of applications. In addition, the scientific adviser was involved in the preparatory work concerning the re-founding of ECOPA (drawing up statutes, preparing for the first General Meeting). Finally, he represented the Foundation at several meetings in Switzerland and abroad.

During the year 2 projects were completed (58/97 and 66/99). Together with those projects completed earlier (1-5/87, 6-15/88, 16/89, 17-20/90, 21-24/91, 25-42/92, 43-44/95, 45-51/96, 53-55/96, 57/97, 59-62/97 64/97, 65/98, 68/99 and 74/00) this brings the total of finished projects to 65 out of 84.

4. Personnel

In 2002 Dr. Raymond F. Miserez resigned as representative of the Federal Veterinary Office on the Administrative Board and the Evaluation Committee since he has taken on a new post at the Federal Office. The latter proposed Ursula Moser, B.Sc. to replace him in both functions, and this nomination was approved. At the end of their terms of office (December 2002) National Councillor Stephanie Baumann and Prof. Andreas Steiger decided not to stand for a further period on the Administrative Board and the Evaluation Committee respectively.

5. 3R-Info-Bulletin

So far the following 3R Information Bulletins have been published in English:

1June 1994Foundation Research 3R
2Sept. 1994mAbs without mice?
3Dec. 1994Gerhard Zbinden and 3R
4April 1995Predicting human drug metabolism
5August 1995Human recombinant antibodies
6Sept. 1995Call for 3R-Research Proposals
7March 1996The three 'R's of Russel & Burch, 1959
8August 1996Regulation of digestion in cell culture
9October 1996Permanent fish cell cultures as novel tools in environmental toxicology
10August 1997Ten years 3R Research Foundation
11March 1999Immunization of laboratory animals
12Sept. 1999Leishmaniasis: Development of an in vitro assay for drug screening
13January 2000Identification of neurotoxic chemicals in cell cultures
14May 2000Transgenic protozoa as an alternative to transgenic animals
15Sept. 2000Aggregating brain cell cultures: Investigation of stroke related brain damage
16January 2001:Housing and husbandry conditions affect stereotypic behaviour in laboratory gerbils
17May 2001Fever in the test tube - towards a human(e) pyrogen test
18Sept. 2001Prevention of adverse effects in pigs after vaccination
19January 2002Phenotype characterisation and welfare assessment of transgenic mice
20May 2002Animal-free screening of biological materials for their contamination by rodent viruses
21Sept. 2002Identification of new human skin irritation markers for tests with human skin reconstructs
22January 2003Environmental enrichment does not affect the variability of animal experimentation data in the Light/Dark test.

6. Financial business

During 2002 around Sfr. 502,000 was used for research grants. An additional Sfr. 80,000 represented an initial payment for setting up an Internet solution for 3R training. Project supervision and information accounted for around Sfr. 95,000 and administrative expenses totalled Sfr. 58,000. Total expenditure was consequently around Sfr. 735,000. The amount spent on research for current projects (Sfr. 472,000) was thus approximately Sfr. 154,000 below budget. This is mainly due to the fact that funding for two projects was Sfr. 130,000 less than expected. Furthermore, the 5% reserve was not paid out owing to the late submission of the final report. On the other hand, it was possible to allot a sum of Sfr. 30,000 to a new project. Operational expenditure for project supervision, information and administration totalled around Sfr. 153,000 and was thus Sfr. 17,000 under budget.

On the income side, the equal financial commitment of the federal authorities and Interpharma constitutes the basis for the Foundation's activities, each body donating a sum of Sfr. 445,000 to 3R.

Income totalled around Sfr. 897,000 (federal authorities and Interpharma together Sfr. 890,000, interest on bank account Sfr. 7,000) while total expenditure amounted to Sfr. 735,000, which gives a positive balance of approximately Sfr. 162,000. The balance of unused research funds therefore rose from around Sfr. 489,000 at the end of 2001 to Sfr. 651,000 at the end of 2002.

The budget for the year 2003 includes a sum of around Sfr. 707,000 for current projects and a maximum of Sfr. 550,000 for new projects.

Overview of grants awarded between 1987 and 2002

By the end of 2002 a total of Sfr. 11,944,309.86 had been granted for projects and other subsidies, of which a total of Sfr. 10,638,121.31 has been paid out so far. Together the federal authorities and Interpharma have contributed Sfr. 12,616,000 to the Foundation since 1987.

10-year overview

7. Financial statements

Profit and loss account 2002Expenditure Income
Federal contribution 445 000.00
Contribution from Interpharma 445 000.00
Total contributions 890 000.00
Interest on bank account 7 536.00
Total income 897 536.00

Research grants501 850.00
Various 3R activities79 866.50
Project supervision and information94 872.95
Administrative expenses58 207.05
Total expenditure734 796.50
Excess income over expenditure162 739.50 
 897 536.00 
Balance as per 31st December 2002AssetsLiabilities
Liquid Assets
Bank 664 904.05
Withholding tax 5 745.10
Accounting apportionment assets 804.00

Accounting apportionment liabilities  18 917.50
Unused project funds
  Carried forward 1. 1. 2002488 796.15
  Excess income over expend162 739.50 651 535.65
Capital of the Foundation  1 000.00
671 453.15  671 453.15

Contingent liabilities
Approved research grants not yet paid out   Sfr. 1 306 188.55.

Münsingen, 18th March 2003

President: signed Dr. Hugo Wick
Secretary: signed E. Diener

8. Auditors' report to the Administrative Board

As 3R Research Foundation's auditors we have examined the books and the annual financial statements (balance sheet and profit and loss account) for the year ending 31st December 2002.

The Administrative Board is responsible for drawing up the financial statements while our task is to check and assess them. We hereby confirm that we are duly qualified to do this and that we have no vested interest in the Foundation.

We have checked the accounts and statements according to the generally accepted principles of accounting, by which this task must be planned and carried out in such a way that important errors in the financial statements are reasonably certain to be identified. We checked the entries and information in the statements in an analytical and investigative way using random samples. Furthermore, we assessed the implementation of standard accounting principles, the main evaluations and the presentation of the accounts as a whole. We are of the opinion that our examination provides a solid basis for our assessment of the accounts and statements of 3R.

In our opinion, the accounts have been kept and the financial statements have been drawn up according to the relevant laws and the statutes and regulations of the Foundation.

We therefore recommend that they be approved.

Gümligen, 12th March 2003
KPMG Fides Peat
signed Willy Beyeler, Cert. Auditor
signed Ursula Waber, Cert. Auditor